IASO Biotherapeutics Licenses CD19 Binder to Cabaletta Bio for Autoimmune Diseases
China-based IASO Biotherapeutics has announced a licensing agreement with US firm Cabaletta Bio Inc. (NASDAQ:...
Henlius Biotech’s HanBeiTai Biosimilar Accepted for Review by CDE
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA)...
Shanghai Launches High-Quality Development Pilot for Public Hospitals
The Shanghai Municipal Health Commission (SHC) has released a notification regarding the public hospital high-quality...
NMPA Introduces Electronic Certificates for Biologics and Narcotic Drugs
The National Medical Products Administration (NMPA) has released a notification regarding the initiation of electronic...
CDE Releases Draft Guidelines for Tumor Therapeutic Vaccine Clinical Trials
The Center for Drug Evaluation (CDE) has released the “Tumor Therapeutic Vaccines Clinical Trial Technical...
SprintRay Raises Over USD 100M in Series D Financing for Dental 3D Printing
Zhejiang-based SprintRay Co., a one-stop digital chair side solution provider for dental institutions, has reportedly...
Pfizer’s Zavicefta Approved in China for Pediatric Complex Intra-Abdominal Infections
US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced that it has received market approval from...
HutchMed Initiates Phase II/III Study of Sovleplenib for Warm AIHA
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced the initiation of a...
Harbour BioMed Licenses Batoclimab to CSPC’s NBP Pharma for Greater China
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...
Guangdong Zhongsheng Receives USPTO Patent for FGFR4 Inhibitor ZSP1241
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced receiving a patent award from...
Simcere Completes Enrollment for Phase III Study of CDK4/6 Inhibitor in mTNBC
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the completion of first-line enrollment for its...
Hengrui Medicine’s Pyrotinib Filing Accepted for Review by NMPA
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its supplementary market filing...
China Resources Partners with Fosun Pharma to Expand Global Healthcare Footprint
China Resources (Holdings) Co. Ltd (HKG: 3320) has entered into a strategic partnership with compatriot...
NMPA Approves JW Therapeutics’ Carteyva for Recurrent Follicular Lymphoma
The National Medical Products Administration (NMPA) has granted another indication approval to China-based JW Therapeutics’...
Innovent’s Cyramza Gains NMPA Approval for Hepatocellular Carcinoma
Innovent Biologics Inc. (HKG: 1801) has announced that the supplementary Biologic License Application (sBLA) for...
Sciwind Biosciences Initiates US Phase I Study for GLP-1 Agonist XW014
China-based Sciwind Biosciences Co., Ltd has announced the initiation and first patient dosing of a...
Fujian Cosunter to Acquire UDCA Capsules Technology from Ruitailai
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced plans to enter into a...
Fujian Cosunter Doses First Patient in Phase I Study of COVID-19 Drug GST-HG171
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that the first patient has...
Salubris Pharmaceuticals’ First-in-Class Anti-Tumor Drug SAL008 Accepted by NMPA
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that a clinical trial filing...
Roche’s Subcutaneous Herceptin Approved in China for HER2-Positive Breast Cancer
Swiss pharmaceutical giant Roche’s (SWX: ROG) Herceptin (trastuzumab, subcutaneous injection) has been approved in China...